Immuneering Corporation (IMRX)
$3.42-3.93%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $124M
- Beta
- 0.39
- P/E (TTM)
- -3.29
- Short % float
- 61.41%
- Days to cover
- 24.2
- SI change
- -0.4%
- 1W
- -11.40%
- 1M
- -22.97%
- vs SPY 1W
- -11.26%
- vs SPY 1M
- -25.48%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 11
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-16.3%
REV YoY-
ROE-27.2%
EPS YoY-
ROA-28.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-3.29
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.16
P/FCF-
EV/EBITDA-2.97
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.91
ALTMAN Z-
CURR RATIO19.47
ND/EBITDA-
BETA0.39
Company news
FAQ
- What is LOPJLB’s current signal on IMRX?
- LOPJLB’s latest quantitative signal on Immuneering Corporation (IMRX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IMRX in?
- Immuneering Corporation (IMRX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Immuneering Corporation (IMRX) do?
- Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specificall…